Brandtree

Acquisition closed

Perrigo acquires Prevacid 24HR (2019)

Perrigo completed the acquisition of Prevacid 24HR on 29 November 2019 for $61.5 million, buying from GSK.[1]

Perrigo bought the branded over-the-counter rights to Prevacid 24HR from GlaxoSmithKline for $61.5 million in cash, capitalising $61.7 million including closing costs as a brand intangible and amortising it over twenty years. What changed hands was the right to sell the brand over the counter rather than the underlying drug, which is how most of Perrigo's branded portfolio has been assembled.

Deal facts

Announced
Not recorded
Closed
Value
$61.5 million (enterprise value)
Buyer
Perrigo
Seller
GSK
Assets
Prevacid 24HR
Regulatory review
None recorded

Ownership changes recorded from this deal

OwnerOwnedRelationshipStakeFromTo
PerrigoPrevacid 24HRowns100%2019-11-29present

Who owns Prevacid 24HR today?

Sources (1) & corrections

Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.

  1. [1] Perrigo Company plc Form 10-K for 2020, note 3 - acquisitions — SEC EDGAR, SEC Form 10-K, published 1 March 2021; retrieved 16 September 2026.

Report a correction Opens a pre-filled GitHub issue. See our corrections policy.